Advertisement

Reactions Weekly

, Volume 1151, Issue 1, pp 3–3 | Cite as

Astellas Pharma Inc has announced that, in the US phase II clinical trial of FG-2216

Media release
  • 12 Downloads

Keywords

Public Health Clinical Trial Hepatitis Marketing Fulminant Hepatitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

REFERENCE

  1. 1.
    Astellas Pharma Inc.Adverse Event of FG-2216 for the Treatment of Anemia. Media Release: 7 May 2007. Available from: URL: http://www.astellas.com

Copyright information

© Adis International limited or Adis Data Information BV 2007

Personalised recommendations